Medical Devices Startups
5,183 companies tagged Medical Devices, with their investors and founders.
Zenflow develops medical devices for treating benign prostatic hyperplasia (BPH) in men, founded from the Stanford Byers Center for Biodesign with a team experienced in medical device development and FDA regulation.
4 investors
Instalimb develops and delivers 3D-printed prosthetics and orthotics using CAD, 3D printing, and machine learning technology to improve accessibility and affordability of mobility devices globally.
4 investors
AI Medical Service Inc. develops AI systems that support image-based diagnosis of endoscopy, primarily for detecting gastrointestinal cancers such as stomach and esophageal cancer. The Japan-based medical device company sells its gastroAI product line to endoscopy and gastroenterology settings, with operations expanding to the US and Southeast Asia.
4 investors
PURMX Therapeutics develops nucleic acid medicines as anti-cancer drugs based on microRNA research and the concept of an "ageing switch" to induce ageing in cancer cells. The Japanese pharmaceutical venture handles drug development functions including non-clinical research, clinical development, CMC, and regulatory affairs.
4 investors
3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets. The company creates therapeutic treatments targeting cancer and other difficult-to-treat diseases.
3 investors
908 Devices manufactures handheld mass spectrometry and chemical analysis devices for rapid detection in defense, security, and hazardous materials response applications. The company serves customs agencies, law enforcement, first responders, and military organizations requiring real-time chemical identification for explosives, toxic substances, and illicit drugs.
3 investors
A-SEEDS is a Shinshu University spin-out developing non-viral gene-modified immune cell therapies, including non-viral CAR-T cell products, to treat pediatric and young-adult cancers, including solid tumors, that lack effective treatments. The company focuses on advancing basic research through non-clinical development into clinical application of these cancer cell therapies.
3 investors
Abzena is an integrated CDMO and CRO providing end-to-end development and cGMP manufacturing services for complex biologics and bioconjugates, including ADCs, AOCs, bispecifics, and HPAPIs. It serves biotech, academic, and pharmaceutical customers across the drug development lifecycle from discovery through commercial manufacturing.
3 investors
Access Optics is an ISO 13485 certified contract design and manufacturing company specializing in medical device innovation and high-temperature probe production.
3 investors
Acclinate builds patient recruitment and data infrastructure for clinical research, connecting pharmaceutical companies with representative, diverse communities to improve research representation and health equity.
3 investors
Tango Belt develops a wearable device that detects serious hip-impacting falls in older adults using fall-risk detection methodology. The product targets elderly populations to improve safety in everyday life.
3 investors
AcuityMD is a MedTech intelligence platform that combines market data, AI-powered insights, and sales workflows to help medical device companies identify opportunities, target physicians, and drive product adoption. It serves commercial teams — sales leaders, reps, operations, marketers, and national accounts — across the medical device industry.
3 investors
Adaptyx develops a minimally-invasive wearable dermal patch that continuously measures biomarkers in interstitial fluid using an array of programmable molecular switches. The continuous data feeds algorithms intended to help clinicians make timelier decisions and reduce avoidable complications and hospital readmissions, replacing traditional lab draws and repeat clinic visits.
3 investors
ADARx is a clinical-stage biopharmaceutical company developing RNA-based medicines using its RNA science expertise and proprietary targeted delivery platforms to silence disease-causing genes. Its pipeline targets chronic conditions including genetic, complement-mediated, cardiovascular, cardiometabolic, central nervous system, and metabolic diseases.
3 investors
ADmit Therapeutics develops the MAP-AD® test, a blood biomarker-based diagnostic tool that predicts progression from mild cognitive impairment to Alzheimer's disease dementia for patients with neurodegenerative diseases. The company operates as a certified clinical laboratory serving healthcare providers and researchers in precision medicine.
3 investors
AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication. It applies a biomarker-guided precision medicine approach to identify patients most likely to benefit and is based in the Berlin area of Germany.
3 investors
Advanced Catheter Therapies develops the Pressana Occlusion Perfusion Catheter, a medical device for targeted endovascular delivery of therapeutic agents to treat peripheral arterial disease and prevent limb amputation. The device is FDA-cleared for below-the-knee use and enables localized infusion of various physician-prescribed medications to prevent restenosis after vessel modification procedures.
3 investors
Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells. Its lead product, AGLE-102, targets dystrophic epidermolysis bullosa, a rare pediatric skin-blistering disease, with potential applications across dermatology, immunology, and protein-deficiency disorders.
3 investors
Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology. The company has been acquired by GSK.
3 investors
Aktiia offers Hilo, a cuff-less, clinically certified wearable band and app for continuous blood pressure monitoring day and night, with an upper-arm cuff for calibration. The system provides trend analysis, doctor-quality reports and lifestyle insights to help users manage and lower high blood pressure.
3 investors
Alafair Biosciences develops naturally-derived hydrogel products for soft-tissue protection during surgery, using a hyaluronic acid and alginate technology to create a protective gliding surface that prevents postoperative tissue tethering and scarring. Its products, sold as a hydrogel sheet and a flowable syringe-deliverable gel, are used by surgeons to protect tendons and peripheral nerves during soft-tissue procedures.
3 investors
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer. The company is advancing Enolen, a drug-eluting implant designed to deliver enzalutamide directly to the prostate with fewer systemic side effects than existing treatments.
3 investors
Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions. The company focuses on gene therapies and other advanced treatment modalities for ophthalmology.
3 investors
Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
3 investors